Defeating Cancer Resistance
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target broad families of oncogenic mutations in clinically validated targets. The company's lead programs focus on non-small cell lung cancer (NSCLC) and glioblastoma (GBM), with silevertinib as its clinical-stage brain-penetrant EGFR inhibitor. Black Diamond trades on Nasdaq under the ticker BDTX.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2023
Jan 2020
Dec 2019
Jan 2019
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Denali Therapeutics is a biotechnology company focused on discovering and developing treatments f...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Biopharmaceutical company developing sustained-release hydrogel therapies targeting retinal disea...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
